Display options
Cite
Hotchkiss AG, Berrigan L, Pelis RM. Organic anion transporter 2 transcript variant 1 shows broad ligand selectivity when expressed in multiple cell lines. Front Pharmacol. 2015;6:216doi: 10.3389/fphar.2015.00216.
Hotchkiss, A. G., Berrigan, L., & Pelis, R. M. (2015). Organic anion transporter 2 transcript variant 1 shows broad ligand selectivity when expressed in multiple cell lines. Frontiers in pharmacology, 6216. https://doi.org/10.3389/fphar.2015.00216
Hotchkiss, Adam G, et al. "Organic anion transporter 2 transcript variant 1 shows broad ligand selectivity when expressed in multiple cell lines." Frontiers in pharmacology vol. 6 (2015): 216. doi: https://doi.org/10.3389/fphar.2015.00216
Hotchkiss AG, Berrigan L, Pelis RM. Organic anion transporter 2 transcript variant 1 shows broad ligand selectivity when expressed in multiple cell lines. Front Pharmacol. 2015 Oct 06;6:216. doi: 10.3389/fphar.2015.00216. eCollection 2015. PMID: 26500550; PMCID: PMC4594013.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2015 Oct 06;6:216. doi: 10.3389/fphar.2015.00216. eCollection 2015.

Organic anion transporter 2 transcript variant 1 shows broad ligand selectivity when expressed in multiple cell lines.

Frontiers in pharmacology

Adam G Hotchkiss, Liam Berrigan, Ryan M Pelis

Affiliations

  1. Department of Pharmacology, Dalhousie University Halifax, NS, Canada.

PMID: 26500550 PMCID: PMC4594013 DOI: 10.3389/fphar.2015.00216

Abstract

Organic anion transporter 2 (OAT2) is likely important for renal and hepatic drug elimination. Three variants of the OAT2 peptide sequence have been described - OAT2 transcript variant 1 (OAT2-tv1), OAT2 transcript variant 2 (OAT2-tv2), and OAT2 transcript variant 3 (OAT2-tv3). Early studies helping to define the ligand selectivity of OAT2 failed to identify the variant used, and the studies used several heterologous expression systems. In preliminary studies using OAT2-tv1, we failed to observe transport of several previously identified substrates, leading us to speculate that ligand selectivity of OAT2 differs with variant and/or heterologous expression system. The purpose was to further investigate the ligand selectivity of the OAT2 variants expressed in multiple cell types. We cloned OAT2-tv1 and OAT2-tv2, but were unsuccessful at amplifying mRNA for OAT2-tv3 from human kidney. OAT2-tv1 and OAT2-tv2 were individually expressed in human embryonic kidney (HEK), Madin-Darby canine kidney (MDCK), or Chinese hamster ovary (CHO) cells. mRNA for OAT2-tv1 and OAT2-tv2 was demonstrated in each cell type transfected with the respective construct, indicating their expression. OAT2-tv1 trafficked to the plasma membrane of all three cell types, but OAT2-tv2 did not. OAT2-tv1 transported penciclovir in all three cell types, but failed to transport para-aminohippurate, succinate, glutarate, estrone-3-sulfate, paclitaxel or dehydroepiandrosterone sulfate - previously identified substrates of OAT2-tv2. Not surprising given its lack of plasma membrane expression, OAT2-tv2 failed to transport any of the organic solutes examined, including penciclovir. Penciclovir transport by OAT2-tv1 was sensitive to large (e.g., cyclosporine A) and small (e.g., allopurinol) organic compounds, as well as organic anions, cations and neutral compounds, highlighting the multiselectivity of OAT2-tv1. The potencies with which indomethacin, furosemide, cyclosporine A and cimetidine inhibited OAT2-tv1 are in good agreement with previous studies using this variant, but inconsistent with studies using OAT2 with an unidentified sequence. This study shows that organic molecules with diverse physicochemical properties interact with OAT2-tv1, making it a likely site of drug interactions. Many previously identified substrates of OAT2 are not transported by OAT2-tv1, suggesting that variant and/or expression system may contribute. Future work should establish the expression pattern and ligand selectivity of OAT2-tv3.

Keywords: Chinese hamster ovary cell; Madin-Darby canine kidney cell; drug transporter; human embryonic kidney cell; multi-selective; organic anion transporter 2; solute carrier family; transcript variant

References

  1. J Biol Chem. 2006 Dec 8;281(49):38071-9 - PubMed
  2. Nat Rev Drug Discov. 2010 Mar;9(3):215-36 - PubMed
  3. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9 - PubMed
  4. Biochem J. 2004 May 15;380(Pt 1):283-7 - PubMed
  5. Drug Metab Dispos. 2015 Jul;43(7):984-93 - PubMed
  6. Mol Pharmacol. 2008 Apr;73(4):1151-8 - PubMed
  7. Kidney Int. 2014 Aug;86(2):350-7 - PubMed
  8. Jpn J Pharmacol. 2002 Jan;88(1):69-76 - PubMed
  9. Am J Physiol Renal Physiol. 2011 Aug;301(2):F378-86 - PubMed
  10. J Pharmacol Sci. 2004 Feb;94(2):197-202 - PubMed
  11. Biochem J. 2011 Jun 1;436(2):305-12 - PubMed
  12. Biol Pharm Bull. 2010;33(3):498-503 - PubMed
  13. J Diabetes Res. 2015;2015:483238 - PubMed
  14. FEBS Lett. 1998 Jun 12;429(2):179-82 - PubMed
  15. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24 - PubMed
  16. Cell Biochem Funct. 2003 Mar;21(1):1-9 - PubMed
  17. Mol Pharmacol. 2014 Jul;86(1):86-95 - PubMed
  18. Pharmacol Res. 2015 Jan;91:78-87 - PubMed
  19. J Pharmacol Exp Ther. 2002 Jun;301(3):797-802 - PubMed
  20. J Pharmacol Exp Ther. 2004 Mar;308(3):1021-9 - PubMed
  21. Drug Metab Dispos. 2005 May;33(5):619-22 - PubMed
  22. J Biol Chem. 2004 Apr 9;279(15):14961-6 - PubMed
  23. Drug Metab Dispos. 2012 Mar;40(3):617-24 - PubMed
  24. Biochem Biophys Res Commun. 2001 May 4;283(2):417-22 - PubMed
  25. Mol Pharmacol. 2015 Apr;87(4):697-705 - PubMed
  26. Eur J Pharmacol. 2003 Mar 28;465(1-2):1-7 - PubMed
  27. J Pharm Pharmacol. 2005 May;57(5):573-8 - PubMed
  28. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8 - PubMed
  29. Mol Pharmacol. 2002 Jul;62(1):7-14 - PubMed
  30. Biopharm Drug Dispos. 2010 Jan;31(1):1-71 - PubMed

Publication Types